Simonsson Otto, Goldberg Simon B, Chambers Richard, Osika Walter, Simonsson Charlotta, Hendricks Peter S
Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Center for Social Sustainability, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.
Psychopharmacology (Berl). 2023 Oct 24. doi: 10.1007/s00213-023-06478-5.
Research on psychedelics has recently shown promising results in the treatment of various psychiatric disorders, but relatively little remains known about the psychiatric risks associated with naturalistic use of psychedelics.
The objective of the current study was to investigate associations between naturalistic psychedelic use and psychiatric risks.
Using a sample representative of the US adult population with regard to sex, age, and ethnicity (N=2822), this study investigated associations between lifetime naturalistic psychedelic use, lifetime unusual visual experiences, and past 2-week psychotic symptoms.
Among respondents who reported lifetime psychedelic use (n=613), 1.3% reported having been told by a doctor or other medical professional that they had hallucinogen persisting perception disorder. In covariate-adjusted linear regression models, lifetime psychedelic use was associated with more unusual visual experiences at any point across the lifetime, but no association was observed between lifetime psychedelic use and past 2-week psychotic symptoms. There was an interaction between lifetime psychedelic use and family (but not personal) history of psychotic or bipolar disorders on past 2-week psychotic symptoms such that psychotic symptoms were highest among respondents who reported lifetime psychedelic use and a family history of psychotic or bipolar disorders and lowest among those who reported lifetime psychedelic use and no family history of psychotic or bipolar disorders.
Although the results in this study should be interpreted with caution, the findings suggest that lifetime naturalistic use of psychedelics might be associated with more unusual visual experiences across the lifetime, as well as more psychotic symptoms in the past 2 weeks for individuals with a family history of psychotic or bipolar disorders and the reverse for those without such a family history. Future research should distinguish between different psychotic and bipolar disorders and should also utilize other research designs (e.g., longitudinal) and variables (e.g., polygenic risk scores) to better understand potential cause-and-effect relationships.
近期关于迷幻剂的研究在治疗各种精神疾病方面显示出了有前景的结果,但对于自然使用迷幻剂所带来的精神风险,人们了解得还相对较少。
本研究的目的是调查自然使用迷幻剂与精神风险之间的关联。
本研究使用了一个在性别、年龄和种族方面代表美国成年人群的样本(N = 2822),调查了终生自然使用迷幻剂、终生异常视觉体验与过去两周内的精神病症状之间的关联。
在报告有终生迷幻剂使用经历的受访者中(n = 613),1.3% 的人报告曾被医生或其他医疗专业人员告知患有致幻剂持续性感知障碍。在协变量调整的线性回归模型中,终生迷幻剂使用与一生中任何时候出现更多异常视觉体验相关,但未观察到终生迷幻剂使用与过去两周内的精神病症状之间存在关联。终生迷幻剂使用与精神病或双相情感障碍的家族(而非个人)病史在过去两周的精神病症状上存在交互作用,即报告有终生迷幻剂使用经历且有精神病或双相情感障碍家族病史的受访者中精神病症状最高,而报告有终生迷幻剂使用经历但无精神病或双相情感障碍家族病史的受访者中症状最低。
尽管本研究结果应谨慎解读,但研究结果表明,终生自然使用迷幻剂可能与一生中更多异常视觉体验相关,对于有精神病或双相情感障碍家族病史的个体,过去两周内还会出现更多精神病症状,而对于无此类家族病史的个体则相反。未来的研究应区分不同的精神病和双相情感障碍,还应采用其他研究设计(如纵向研究)和变量(如多基因风险评分),以更好地理解潜在的因果关系。